COVID-19 vaccine Nuvaxovid: temporary authorisation from 12 years of age and as a booster

9 September 2022 – Swissmedic approved Nuvaxovid, the COVID-19 vaccine from Novavax, for young people ages 12 and over with immediate effect. Furthermore, Nuvaxovid can also be administered as a booster following basic immunisation for people aged 18 and over.

For more information, see here.